Tricyclic functional dyes for contrast enhancement in optical imaging

ABSTRACT

This invention provides functional dyes of the general formula: ##STR1## wherein R 1 , R 2 , and R 5  may be the same or different and are selected from the group consisting of hydrogen, C 1  -C 10  alkyl, C 1  -C 10  alkoxyl, hydroxyl, C 1  -C 10  hydroxyalkyl, C 1  -C 10  alkoxyalkyl, C 1  -C 10  aryl, carboxyl, C 1  -C 10  carboxylalkyl, halogen, nitro, C 1  -C 10  alkoxycarbonyl, mercapto, C 1  -C 10  mercaptoalkyl, C 1  -C 10  alkylthio, sulfonate, and --(CH 2 ) m  --N(R 6 )(R 7 ) wherein R 6  and R 7  are independently hydrogen or C 1  -C 10  alkyl, C 1  -C 10  acyl, and R 6  and R 7  are capable of forming 5, 6, or 7 membered rings which may optionally be substituted with --O--, --NR 8 , or --S--; R 3  and R 4  may be the same or different and are selected from the group consisting of C 1  -C 10  alkyl, C 1  -C 10  hydroxyalkyl, C 1  -C 10  alkoxyalkyl, C 1-C   10  aryl, C 1  -C 10  carboxylalkyl, C 1  -C 10  alkyl sulfonate, mercapto alkyl and --(CH 2 ) m  N(R 6 )(R 7 ); W 1  and W 2  may be the same or different and are selected from the group consisting of --S--, --O--, --Se--, --Te--, --NR 8  and C(R 9 )(R 10 ); and m is about 0-10; R 8  is hydrogen, C 1  -C 10  alkyl, C 1  -C 10  alkoxy, C 1  -C 10  mercaptoalkyl, hydroxyl, C 1  -C 10  hydroxyalkyl, C 1  -C 10  alkoxyalkyl, C 1  -C 10  aryl, C 1  -C 10  carboxylalkyl, C 1  -C 10  alkoxycarbonyl, C 1  -C 10  alkylthio, and --(CH 2 ) m  --N(R 6 )(R 7 ); R 9  and R 10  are independently hydrogen, C 1  -C 10  alkyl, C 1  -C 10  alkoxyl, C 1  -C 10  hydroxyalkyl, C 1  -C 10  alkoxyalkyl, C 1  -C 10  carboxyalkyl, C 1  -C 10  alkoxycarbonyl, and --(CH 2 ) m  --N(R 6 )(R 7 ); and A is selected from the group consisting of --(CH 2 ) m , --C(R 9 )(R 10 ), --(CH 2 ) m  --N(R 6 )(R 7 ) --O--, --S--, or --NR 8 .

FIELD OF THE INVENTION

The invention is in the field of tomographic imaging. Particularly, theinvention is in the field of optical imaging. Most particularly, theinvention provides dyes for use in the field of optical imaging.

BACKGROUND OF THE INVENTION

Optical imaging with dyes permit visualization of biological activities(Blasdel, G. G.; Salama, G. Nature 1986, 321, 579, Grinvald, A.;Frostig, E. L.; Hildesheim, R. Physiological Reviews 1988, 68, 1285,Kauer, J. S. Nature 1988, 331, 166, Lieke, E. E.; Frostig, R. D.;Arieli, A.; Ts'o, D. Y.; Hildesheim, R. and Grinvald, A. Annu. Rev.Physiol. 1989, 51, 543 and reference therein). Dyes that are sensitiveto physicochemical environments (such as pressure, cell membranepotential, ion concentration, acidity, partial pressure of oxygen andetc.), are subject to changes in absorption or emission of light. Theresulting changes act as optical probes to transform biologicalactivities into optical signals that can be converted into opticalimages.

Cyanine dyes with intense absorption and emission in the near-IR region(600-1300 nm) are particularly useful because biological tissues areoptically transparent in this region. Indocyanine Green (ICG) (I) forexample, with absorption maxima at around 810 nm (the isosbestic pointof the hemoglobin/deoxyhemoglobin), has been used for monitoring cardiacoutput, hepatic function, and liver blood flow. After intravenousinjection, ICG is rapidly bound by plasma proteins and remains in theblood through one circulation of heart and lungs. ICG is then taken upby hepatic parenchymal cells and secreted entirely into the bile (Osol,A.; Pratt, R. The United States Dispensatory Philadelphia, Toronto: J.B. Lippincott Company, 1973, 615).

Despite ICG's promising application, aqueous solutions of indocyaninegreen rapidly decomposes when irradiated with incandescent light. Also,ICG itself does not localize in any particular tissue. ##STR2##

Targeting groups can be introduced to cyanine and indocyanine dyes ifessential linkers are present at a convenient site that will notinterfere with the optical activity. Conventionally, these spacers havebeen attached at the nitrogen atom in the heterocyclic moiety.(Mujumdar, R. B.; Ernst, L. A.; Mujumdar, S. R.; Lewis, C. J.; Waggoner,A. S. Bioconjugate Chem. 1993, 4, 105). To effectively label targetinggroups, a single spacer between the dye and the targeting group ispreferred, and typically involves a multi-step synthesis (Mujumdar, R.B.; Ernst, L. A.; Mujumdar, S. R.; Lewis, C. J.; Waggoner, A. S.Bioconjugate Chem. 1993, 4, 105). Additional problems also arise fromthe photo-instability of the long olefin chain (Matsuoka, M. In InfraredAbsorbing Dyes; Plenum: New York, 1990; Chapter 3). Cyanine dyes withshorter olefin chains are relatively stable, but their absorption andemission do not fall within the optical window (600-1300 nm) necessaryfor optical imaging.

There is a need to design stable dyes that possess desirablephotophysical properties, stability, and targeting ability. The presentinvention overcomes the technical problems mentioned previously byincorporating a bifunctional spacer, and imposing rigidity on thepolyene portion of the cyanine and indocyanine dyes.

SUMMARY OF THE INVENTION

This invention provides functional dyes of the general formula: ##STR3##wherein R1, R2, and R⁵ may be the same or different and are selectedfrom the group consisting of hydrogen, C₁ -C₁₀ alkyl, C₁ -C₁₀ alkoxyl,hydroxyl, C₁ -C₁₀ hydroxyalkyl, C₁ -C₁₀ -alkoxyalkyl, C₁ -C₁₀ aryl,carboxyl, C₁ -C₁₀ carboxylalkyl, halogen, nitro, C₁ -C₁₀ alkoxycarbonyl,mercapto, C₁ -C₁₀ mercaptoalkyl, C₁ -C₁₀ alkylthio, sulfonate, and--(CH₂)_(m) --N(R⁶)(R⁷) wherein R⁶ and R⁷ are independently hydrogen orC₁ -C₁₀ alkyl, C₁ -C₁₀ acyl, and R⁶ and R⁷ are capable of forming 5, 6,or 7 membered rings which may optionally be susbstituted with --O--,--NR⁸, or --S--; R³ and R⁴ may be the same or different and are selectedfrom the group consisting of C₁ -C₁₀ alkyl, C₁ -C₁₀ hydroxyalkyl, C₁-C₁₀ alkoxyalkyl, C₁ -C₁₀ aryl, C₁ -C₁₀ carboxylalkyl, C₁ -C₁₀ alkylsulfonate, mercapto alkyl and --(CH₂)_(m) N(R⁶)(R⁷); W¹ and W² may bethe same or different and are selected from the group consisting of--S--, --O--, --Se--, --Te--, --NR⁸ and C(R⁹)(R¹⁰); and m is about 0-10;R⁸ is hydrogen, C₁ -C₁₀ alkyl, C₁ -C₁₀ alkoxy, C₁ -C₁₀ mercaptoalkyl,hydroxyl, C₁ -C₁₀ hydroxyalkyl, C₁ -C₁₀ alkoxyalkyl, C₁ -C₁₀ aryl, C₁-C₁₀ carboxylalkyl, C₁ -C₁₀ alkoxycarbonyl, C₁ -C₁₀ alkylthio, and--(CH₂)_(m) --N(R⁶)(R⁷); R⁹ and R¹⁰ are independently hydrogen, C₁ -C₁₀alkyl, C₁ -C₁₀ alkoxyl, C₁ -C₁₀ hydroxyalkyl, C₁ -C₁₀ alkoxyalkyl, C₁-C₁₀ carboxyalkyl, C₁ -C₁₀ alkoxycarbonyl; and A is selected from thegroup consisting of --(CH₂)_(m) --, --C(R⁹)(R¹⁰), --(CH₂)_(m)--N(R⁶)(R⁷), --O--, --S--, or --NR⁸. Also provided are methods of usingdyes of the invention comprising administering a diagnosticallyeffective amount of the dye to a patient and visualizing the dye.

DETAILED DESCRIPTION OF INVENTION

Cyanine dyes are symmetric molecules with two heterocyclic base groupslinked by a conjugated carbon chain. These dyes absorb intensely fromthe visible to near-infrared (NIR) region, depending strongly on thelength of the carbon chain. Bathochromic shift is often found whennumber of C═C unit increases (Matsuoka, M. In Infrared Absorbing Dyes;Plenum: New York, 1990; Chapter 2 & 3). Other structural variations thatcause bathochromic shift can also be introduced into these dyes.Typically, electron donating or electron withdrawing functional groupssuch as alkyl, alkoxyl, alkylthio, halogen, cyano, alkoxycarbonyl, andnitro can be substituted at the appropriate electron-rich or electrondeficient centers at the polyene portion of the molecule.

The cyanine dyes are generally prepared from condensation reactionbetween quaternary salts of heterocyclic base and bis-aldehyde or Schiffbase in acetic acid/acetic anhydride (Keyes, G. H. ##STR4## U.S. Pat.No. 2,251,286, 1941; Heseltine, D. W.; Brooker, L. G. S. U.S. Pat. No.2,895,955, 1959; Reynolds, G. A.; Drexhage, K. H. J. Org. Chem. 1977,42, 885). The bicyclic cyanine dyes of the present invention can beprepared by the condensation of the thiazolium (2) and the diketone (3).Asymmetric dyes with linkage groups can be prepared in a similar mannerwith additional synthetic steps (Mujumdar, R. B.; Ernst, L. A.;Mujumdar, S. R.; Lewis, C. J.; Waggoner, A. S. Bioconjugate Chem. 1993,4, 105).

The starting materials for the bicyclic key intermediate 4 can beprepared by the well known procedures as illustrated in Schemes 1-3.##STR5##

Recently, Narayanan and Patonay have demonstrated the synthesis of newcyanine dyes using 2-chloro-1-formyl-3-(hydroxymethylene) cyclohex-1-eneas a template (Narayanan, N.; Patonay, G. J. Org. Chem. 1995, 60, 2391).Several symmetric dyes were prepared in high yields. Like croconiumdyes, the central part of these dyes contain a cyclic ring with one C═Cbond and a chloride atom. Their results show that introduction of acroconic moiety into the conjugating bridge significantly shift theabsorption to longer wavelengths.

The present invention describes the use of ring template strategy tosynthesize stable cyanine dyes with desirable photophysical andtargeting properties. Simple condensation between a quaternary salt of aheterocyclic base and the template ring will give desirable dye productsthat are conformationally rigid. The extended conjugated π systemthrough this centrally located ring(s) will give intensely coloredmaterials. With appropriate coupling groups such as acid halides, activeesters, alcohols, aldehydes, amines, aryl halides, carboxylic acids,n-carboxyanhydrides, disulfides, hydrazides, iodoacetamides,isothiocyanates, imadates, maleimides, nitrenes, sulfonyl chlorides andso forth, the dye moiety can effectively label biological materials. Thering system may have at least one C═C bond. The ring system may alsocontain Group III, IV, V or VI elements in order to further shift theabsorption maxima to longer wavelength. The ring system can also be afused ring structure with five, six or seven membered rings. The ringstructure can also be substituted with acid halides, active esters,alcohols, aldehydes, amines, aryl halides, carboxylic acids,n-carboxyanhydrides, disulfides, hydrazides, iodoacetamides,isothiocyanates, imadates, maleimides, nitrenes, sulfonyl chloride andso forth that are essential for conjugation with targeting groups(biomolecules).

Biomolecules for use with the dyes refer to all natural and syntheticmolecules that play a role in biological systems. Biomolecules includehormones, amino acids, peptides, peptidomimetics, glycomimetics,vitamins, carbohydrates, proteins, deoxyribonucleic acid (DNA),ribonucleic acid (RNA), lipids, albumins, polyclonal antibodies,receptor molecules, receptor binding molecules, monoclonal antibodiesand aptamers. Specific examples of biomolecules include insulins,prostaglandins, growth factors, liposomes and nucleic acid probes.Examples of synthetic polymers include polylysine, aborols, dendrimers,and cyclodextrins. The advantages of using biomolecules include enhancedtissue targeting through specificity and delivery. Coupling of the dyesto biomolecules can be accomplished by several known methods (e.g.,Krejcarek and Tucker Biochem. Biophys. Res. Comm, 30, 581 (1977);Hnatowich, et al. Science, 220, 613 (1983). Typically, a nucleophilicgroup is reacted with an electrophilic group to form a covalent bondbetween the biomolecule and the dye. Examples of nucleophilic groupsinclude amines, anilines, alcohols, phenols, thiols and hydrazines.Electrophilic group examples include halides, disulfides, epoxides,maleimides, acid chlorides, anhydrides, mixed anhydrides, activatedesters, imidates, isocyanates and isothiocyanates.

Examples of suitable alkyl groups for use with the invention includemethyl, ethyl, propyl, isopropyl, butyl, cyclohexyl, heptyl and octyl.Suitable alkoxyl groups include methoxyl, ethoxyl, propoxyl, butoxyl,pentoxyl, hexoxyl, heptoxyl and octoxyl. Hydroxyalkyl groups suitablefor use with the invention include both mono and poly hydroxyalkyls suchas hydroxyethyl, 2-hydroxypropyl, 2,3-dihydroxypropyl,2,3,4-trihydroxybutyl, tris (hydroxymethyl) methyl and2-hydroxy-1-hydroxymethyl-ethyl. Suitable alkoxyalkyl groups includemethoxymethyl, 2,3-dimethoxypropyl, tris (methoxymethyl) methyl, and2-methoxy-1-methoxymethyl-ethyl. Amino groups suitable for use with theinvention include aminoalkyl such as amino methyl, amino ethyl, aminopropyl, hydroxyamino such as 1-amino-2,3 propandiol, 1-amino-2-ethanol,and 1-amino-3-propanol and amino acids such as alanine, aspartic acid,glycine and lysine. Carboxyalkyls include acetate, hexanoate,propionate, and butyrate. Carbohydrates, monosaccharides, andpolysaccharides such as glucose, maltose, lactose and amylose. Arylgroups include phenyl and naphthyl. Alkoxycarbonyl include methyl ester,ethyl ester, propyl ester and butyl ethyl ester. Halogen groups includechlorine, fluorine, bromine and iodine. Alkylamido groups include groupssuch as methyl amido, ethyl amido, propyl amido and, butyl amide.Alkylthio groups include methyl thio, ethyl thio, propyl thio, and butylthio. Aminoalkyls include NR⁶ R⁷ where R⁶ and R⁷ can be hydrogen or C₁-C₁₀ alkyl and R⁶ and R⁷ are capable of forming 5, 6, or 7 memberedrings which can be further substituted by a heteroatom such as O, --NR⁸or S, wherein R⁸ is hydrogen, alkyl, alkoxyl, hydroxyl, hydroxyalkyl,aminoalkyl, alkoxyalkyl, alkylamido, aryl, carboxyl, carboxyalkyl,halogen, nitro, alkoxycarbonyl, mercapto, alkylthio and alkyl sulfonate.

The compositions of the invention can be formulated into diagnosticcompositions for enteral or parenteral administration. Thesecompositions contain an effective amount of the dye along withconventional pharmaceutical carriers and excipients appropriate for thetype of administration contemplated. For example, parenteralformulations advantageously contain a sterile aqueous solution orsuspension of dye according to this invention. Parenteral compositionsmay be injected directly or mixed with a large volume parenteralcomposition for systemic administration. Such solutions also may containpharmaceutically acceptable buffers and, optionally, electrolytes suchas sodium chloride.

Formulations for enteral administration may vary widely, as is wellknown in the art. In general, such formulations are liquids whichinclude an effective amount of the dye in aqueous solution orsuspension. Such enteral compositions may optionally include buffers,surfactants, thixotropic agents, and the like. Compositions for oraladministration may also contain flavoring agents and other ingredientsfor enhancing their organoleptic qualities.

The diagnostic compositions are administered in doses effective toachieve the desired enhancement. Such doses may vary widely, dependingupon the particular dye employed, the organs or tissues which are thesubject of the imaging procedure, the imaging procedure, the imagingequipment being used, and the like.

The diagnostic compositions of the invention are used in theconventional manner. The compositions may be administered to a patient,typically a warm-blooded animal, either systemically or locally to theorgan or tissue to be imaged, and the patient then subjected to theimaging procedure.

The following examples illustrate the specific embodiments of theinvention described in this document. As would be apparent to skilledartisans, various changes and modifications are possible and arecontemplated within the scope of the invention described.

EXAMPLES Example I Synthesis of Bicyclic Cyanine Dye Wherein A and B are--CH₂ -- Groups and R⁵ is Methoxycarbonyl

A mixture of compound 4 (2.2 g, 10 mmole) and 2 mL of triethylamine in10 mL of acetonitrile is added with 1,2-dimethylbenzothiazolium iodide(3.0 g, 10.3 mmole). The reaction mixture is slowly heated to reflux for16 hours. The final product is purified by recrystallization orchromatography.

Example II Synthesis of Bicyclic Cyanine Dye Wherein A is --CH₂ --Group, B is --O--, and R⁵ is Methoxycarbonyl

A mixture of Compound 5 (2.2 g, 10 mmole) and 2 mL of triethylamine in10 mL of acetonitrile is added with 1,2-dimethylbenzothiazolium iodide(3.0 g, 10.3 mmole). The reaction mixture is slowly heated to reflux for16 hours. The final product is purified by recrystallization orchromatography.

Example III Synthesis of Cyanine Dye Wherein A is --CH₂ -- Group, B is--N⁸, R⁵ is --H, and R⁸ is --(CH2)CO2CH3 Group

A mixture of compound 6 (2.4 g, 10 mmole) and 2 mL of triethylamine in10 mL of acetonitrile is added with 1,2-dimethylbenzothiazolium iodide(2.9 g, 10.3 mmole). The reaction mixture is slowly heated to reflux for16 hours. The final product is purified by recrystallization orchromatography.

Although the invention has been described with respect to specificmodifications, the details thereof are not to be construed aslimitations, for it will be apparent that various equivalents, changesand modifications may be resorted to without departing from the spiritand scope thereof, and it is understood that such equivalent embodimentsare to be included therein.

What is claimed is:
 1. A diagnostic composition comprising a compound ofthe formula: ##STR6## wherein R¹, R², and R⁵ may be the same ordifferent and are selected from the group consisting of hydrogen, C₁-C₁₀ alkyl, C₁ -C₁₀ alkoxyl, hydroxyl, C₁ -C₁₀ hydroxyalkyl, C₁ -C₁₀alkoxyalkyl, C₁ -C₁₀ aryl, carboxyl, C₁ -C₁₀ carboxylalkyl, halogen,nitro, C₁ -C₁₀ alkoxycarbonyl, mercapto, C₁ -C₁₀ mercaptoalkyl, C₁ -C₁₀alkylthio, sulfonate, and --(CH₂)_(m) --N(R⁶)(R⁷) wherein R⁶ and R⁷ areindependently hydrogen or C₁ -C₁₀ alkyl, C₁ -C₁₀ acyl, and R⁶ and R⁷ arecapable of forming 5, 6, or 7 membered rings which may optionally besubstituted with --O--, --NR⁸, or --S--; R³ and R⁴ may be the same ordifferent and are selected from the group consisting of C₁ -C₁₀ alkyl,C₁ -C₁₀ hydroxyalkyl, C₁ -C₁₀ alkoxyalkyl, C₁ -C₁₀ aryl, C₁ -C₁₀carboxyalkyl, C₁ -C₁₀ alkyl sulfonate, mercapto alkyl and --(CH₂)_(m)N(R⁶)(R⁷); W¹ and W² may be the same or different and are selected fromthe group consisting of --S--, --O--, --Se--, --Te--, --NR⁸ andC(R⁹)(R¹⁰); and m is about 0-10; R⁸ is hydrogen, C₁ -C₁₀ alkyl, C₁ -C₁₀alkoxy, C₁ -C₁₀ mercaptoalkyl, hydroxyl, C₁ -C₁₀ hydroxyalkyl, C₁ -C₁₀alkoxyalkyl, C₁ -C₁₀ aryl, C₁ -C₁₀ carboxylalkyl, C₁ -C₁₀alkoxycarbonyl, C₁ -C₁₀ alkylthio, and --(CH₂)_(m) --N(R⁶)(R⁷); R⁹ andR¹⁰ are independently hydrogen, C₁ -C₁₀ alkyl, C₁ -C₁₀ alkoxyl, C₁ -C₁₀hydroxyalkyl, C₁ -C₁₀ alkoxyalkyl, C₁ -C₁₀ carboxyalkyl, C₁ -C₁₀alkoxycarbonyl, and --(CH₂)_(m) --N(R⁶)(R⁷); and A is selected from thegroup consisting of --(CH₂)_(m), --C(R⁹)(R¹⁰), --(CH₂)_(m) --N(R⁶)(R⁷),--O--, --S--, or --NR⁸.
 2. The composition of claim 1 wherein R¹, R² andR⁵ are independently hydrogen, C₁ -C₁₀ alkyl, hydroxyl, C₁ -C₁₀ alkoxyl,carboxyl, halogen, nitro, sulfonate, or --(CH₂)_(m) --N(R⁶)(R⁷) whereinm is about 0-10; R³ and R⁴ are independently C₁ -C₁₀ alkyl, C₁ -C₁₀hydroxyalkyl, C₁ -C₁₀ carboxyalkyl, or --(CH₂)_(m) --N(R⁶)(R⁷); R⁶ andR⁷ are independently hydrogen, C₁ -C₁₀ alkyl, C₁ -C₁₀ acyl, andhydroxyalkyl; W¹ and W² are independently --S-- or --C(R⁹ (R¹⁰) whereinR⁹ and R¹⁰ are independently hydrogen, C₁ -C₁₀ alkyl, C₁ -C₁₀hydroxyalkyl, C₁ -C₁₀ carboxyalkyl or --(CH₂)_(m) --N(R⁶)(R⁷); m isabout 1-10; R⁸ is hydrogen, C₁ -C₁₀ alkyl, C₁ -C₁₀ hydroxyalkyl, C₁ -C₁₀carboxyalkyl or --(CH₂)_(m) --N(R⁶)(R⁷); and A may be --(CH₂)_(m) or--(CH₂)_(m) N(R⁶)(R⁷).
 3. The composition of claim 2 wherein R¹ ishydrogen; R² is hydrogen; R³ is methyl; R⁴ is methyl; R⁵ ismethoxycarbonyl; W¹ is --S--; W² is --S--; and A is --CH₂ --.
 4. Thecomposition of claim 2 wherein R¹ is hydrogen; R² is hydrogen; R³ ismethyl; R⁴ is methyl; R⁵ is methoxycarbonyl; W¹ is --S--; W² is --S--;and A is --O--.
 5. The composition of claim 2 wherein R¹ is hydrogen; R²is hydrogen; R³ is methyl; R⁴ is methyl; W¹ is --S--; W² is --S--; and Ais --NR⁸, wherein --R⁸ is carboxymethyl.
 6. A method of imaging apatient comprising the administration of a diagnostically effectiveamount of a compound of the formula: ##STR7## wherein R¹, R², and R⁵ maybe the same or different and are selected from the group consisting ofhydrogen, C₁ -C₁₀ alkyl, C₁ -C₁₀ alkoxyl, hydroxyl, C₁ -C₁₀hydroxyalkyl, C₁ -C₁₀ alkoxyalkyl, C₁ -C₁₀ aryl, carboxyl, C₁ -C₁₀carboxylalkyl, halogen, nitro, C₁ -C₁₀ alkoxycarbonyl, mercapto, C₁ -C₁₀mercaptoalkyl, C₁ -C₁₀ alkylthio, sulfonate, and --(CH₂)_(m) --N(R⁶)(R⁷)wherein R⁶ and R⁷ are independently hydrogen or C₁ -C₁₀ alkyl, C₁ -C₁₀acyl, and R⁶ and R⁷ are capable of forming 5, 6, or 7 membered ringswhich may optionally by substituted with --O--, --NR⁸, or --S--; R³ andR⁴ may be the same or different and are selected from the groupconsisting of C₁ -C₁₀ alkyl, C₁ -C₁₀ hydroxyalkyl, C₁ -C₁₀ alkoxyalkyl,C₁ -C₁₀ aryl, C₁ -C₁₀ carboxylalkyl, C₁ -C₁₀ alkyl sulfonate, mercaptoalkyl and --(CH₂)_(m) N(R⁶)(R⁷); W¹ and W² may be the same or differentand are selected from the group consisting of --S--, --O--, --Se--,--Te--, --NR⁸ and C(R⁹)(R¹⁰); and m is about 0-10; R⁸ is hydrogen, C₁-C₁₀ alkyl, C₁ -C₁₀ alkoxy, C₁ -C₁₀ mercaptoalkyl, hydroxyl, C₁ -C₁₀hydroxyalkyl, C₁ -C₁₀ alkoxyalkyl, C₁ -C₁₀ aryl, C₁ -C₁₀ carboxylalkyl,C₁ -C₁₀ alkoxycarbonyl, C₁ -C₁₀ alkylthio, and --(CH₂)_(m) --N(R⁶)(R⁷);R⁹ and R¹⁰ are independently hydrogen, C₁ -C₁₀ alkyl, C₁ -C₁₀ alkoxyl,C₁ -C₁₀ hydroxyalkyl, C₁ -C₁₀ alkoxyalkyl, C₁ -C₁₀ carboxyalkyl, C₁ -C₁₀alkoxycarbonyl, and --(CH₂)_(m) --N(R⁶)(R⁷); and A is selected from thegroup consisting of --(CH₂)_(m), --C(R⁹)(R¹⁰), --(CH₂)_(m) --N(R⁶)(R⁷),--O--, --S--, or --NR⁸.
 7. The method of claim 6 wherein R¹, R² and R⁵are independently hydrogen, C₁ -C₁₀ alkyl, hydroxyl, C₁ -C₁₀ alkoxyl,carboxyl, halogen, nitro, sulfonate, or --(CH₂)_(m) --N(R⁶)(R⁷) whereinm is about 0-10; R³ and R⁴ are independently C₁ -C₁₀ alkyl, C₁ -C₁₀hydroxyalkyl, C₁ -C₁₀ carboxyalkyl or --(CH₂)_(m) --N(R⁶)(R⁷); R⁶ and R⁷are independently hydrogen, C₁ -C₁₀ alkyl, C₁ -C₁₀ acyl, andhydroxyalkyl; X is --O--, --NR⁸ or --S--; W¹ and W² are independently--S-- or --C(R⁹)(R¹⁰) wherein R⁹ and R¹⁰ are independently hydrogen, C₁-C₁₀ alkyl, C₁ -C₁₀ hydroxyalkyl, C₁ -C₁₀ carboxyalkyl, or --(CH₂)_(m)--N(R⁶)(R⁷); m is about 1-10; R⁸ is hydrogen, C₁ -C₁₀ alkyl, C₁ -C₁₀hydroxyalkyl, C₁ -C₁₀ carboxyalkyl, or --(CH₂)_(m) --N(R⁶)(R⁷); and Amay be --(CH₂)_(m) or --(CH₂)_(m) N(R⁶)(R⁷).
 8. The method of claim 7wherein R¹ is hydrogen; R² is hydrogen; R³ is methyl; R⁴ is methyl; R⁵is methoxycarbonyl; W¹ is --S--; W² is --S--; and A is --CH₂ --.
 9. Themethod of claim 7 wherein R¹ is hydrogen; R² is hydrogen; R³ is methyl;R⁴ is methyl; R⁵ is methoxycarbonyl; W¹ is --S--; W² is --S--; and A is--O--.
 10. The method of claim 7 wherein R¹ is hydrogen; R² is hydrogen;R³ is methyl; R⁴ is methyl; W¹ is --S--; W² is --S--; and A is --NR⁸,wherein R⁸ is carboxymethyl.